Organic compounds

A method of inhibiting human stearoyl-CoA desaturase (hSCD) activity comprising contacting a source of hSCD with a compound of Formula (I):

• wherein,
• V is selected from —N(R5)C(O)—, —C(O)N(R5)—, —OC(O)N(R5)—, —N(R5)C(O)O—, —N(R5)C(O)N(R5)—, —O—, —N(R5)—, —S—, —S(O)t, —N(R5)S(O)t, —S(O)tN(R5)—, —OS(O)t, —OS(O)2N(R5)—, —C(O)—, —OC(O)—, —C(O)O—, —N(R5)C(═N(R5a))NR5—, —N(R5)C(═S)NR5—, —N(R5)((R5a)N═)C—, —C(═N(R5a))N(R5)—, alkylene, alkenylene, alkynylene, aryl, heteroaryl, cycloalkyl, heterocyclyl or a direct bond;
• W is selected from —N(R5)C(O)—, —C(O)N(R5)—, —OC(O)N(R5)—, —N(R5)C(O)O—, —N(R5)C(O)N(R5)—, —O—, —N(R5)—, —S—, —S(O)t, —N(R5)S(O)t, —S(O)tN(R5)—, —OS(O)2N(R5)—, —C(O)—, —OC(O)—, —C(O)O—, —N(R5)C(═N(R5a))NR5—, —N(R5)((R5a)N═)C—, —C(═N(R5a))N(R5)—, aryl, heteroaryl, heterocyclyl, alkynylene, alkenylene, alkylene or a direct bond;
• X is selected from C(H) or N;
• Y is selected from S, N(H) or N(CH3);
• p is 0, 1, 2, or 3;
• t is 1 or 2;
• R1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl, and heteroarylalkyl;
• or R1 is a multi-ring structure having 2 to 4 rings wherein the rings are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl and where some or all of the rings may be fused to each other;
• R2 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, haloalkyl, aralkyl, heterocyclyl, heterocyclylalkyl, heteroaryl and heteroarylalkyl;
• R3 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkoxy, hydroxyalkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, aryl, aralkyl, heteroaryl, halo, haloalkyl, haloalkoxyl, cyano and —N(R5)2;
• R4 is selected from the group consisting of alkyl, hydroxyalkyl, cycloalkylalkyl, aralkyl, halo, haloalkyl, —OCF3 and —OC(H)F2;
• R5 is selected from the group consisting of hydrogen, aryl, alkyl, heteroaryl, heterocyclyl, haloalkyl, hydroxyalkyl, cycloalkylalkyl and aralkyl;
• R5a is selected from the group consisting of hydrogen, alkyl, cycloalkylalkyl and cyano;
• a stereoisomer, enantiomer or tautomer thereof, a pharmaceutically acceptable salt thereof.